LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024.
Labcorp (LH) came out with quarterly earnings of $3.45 per share, beating the Zacks Consensus Estimate of $3.40 per share. This compares to earnings of $3.30 per share a year ago.
Labcorp forecast 2025 revenue above Wall Street estimates after reporting fourth-quarter results beat on Thursday, banking on robust demand for its diagnostic tests.
Beyond analysts' top -and-bottom-line estimates for Labcorp (LH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
In the fourth quarter of 2024, LH is likely to have witnessed strong growth in both diagnostics and biopharma laboratory services.
Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investors are increasingly optimistic about LH due to its focus on high-growth areas and strategic partnerships.
LH announces strategic agreement with Graves Gilbert Clinic for lab operations.
LH's new H5 bird flu test, developed in collaboration with the CDC, is now available in the United States.
Labcorp is set to acquire select assets of MAWD Pathology Group.